Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIDE-Biliary02: rilvegostomig or durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer
CTR20260345Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Mar 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of rilvegostomig in biliary cancer, cholangiocarcinoma (CCA), gallbladder cancer, sponsored by AstraZeneca. Started Mar 2026; status: active.
02
Drugs
rilvegostomig
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on CTR20260345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260345.